Diffuse Large B-Cell Lymphoma, NOS · line 3 · Lisocabtagene maraleucel (liso-cel) CAR-T for r/r LBCL ≥3L (TRANSCEND NHL 001)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	3
Track	aggressive
Linked regimen	`REGIMEN-LISOCEL-DLBCL-3L`

ID	`IND-DLBCL-3L-LISO-CEL-CART`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-DLBCL-NOS`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025` `SRC-ZUMA-1-NEELAPU-2017` `SRC-ZUMA-7-LOCKE-2022`

Notes

STUB — pending Clinical Co-Lead sign-off. 3L+ aggressive-track CD19 CAR-T option for r/r DLBCL. Liso-cel preferred for safety; axi-cel already in KB (IND-DLBCL-3L-AXICEL-CART). Missing entity flag: dedicated REG-LISO-CEL — author in PROD-2.

Used By

Indication

IND-DLBCL-2L-LISOCEL - IND-DLBCL-2L-LISOCEL